• RIG-I Drives Renal Fibrosis via c-Myc and TGF-β/Smad Signali

  2026-04-30

  This study reveals that RIG-I is upregulated in fibrotic kidneys, where it promotes inflammatory cytokine production and fibroblast activation through c-Myc-mediated TGF-β/Smad signaling. The findings clarify a molecular axis in renal fibrosis and highlight RIG-I as a potential target for chronic kidney disease intervention.

• Angiotensin II (A1042): Protocols and QC for Vascular Models

  2026-04-30

  Angiotensin II (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe) is an octapeptide hormone used to induce and study hypertension mechanisms, vascular smooth muscle cell hypertrophy, and cardiovascular remodeling in experimental models. It is best suited for controlled in vitro and in vivo research workflows where precise vasopressor and GPCR agonist activity is required. Not recommended for diagnostic or clinical applications.

• Cholesterol Impedes Lipid Nanoparticle Trafficking in Cells

  2026-04-29

  This study identifies cholesterol as a key barrier to efficient intracellular trafficking of lipid nanoparticles (LNPs) for nucleic acid delivery. Using a sensitive tracking platform, the researchers reveal how high cholesterol content leads to LNP entrapment in peripheral endosomes, reducing delivery efficiency and highlighting opportunities for improved LNP design.

• Angiotensin II (A1042): Practical Use in Vascular Research

  2026-04-29

  Angiotensin II (SKU A1042) is a defined octapeptide used to model hypertension, vascular smooth muscle cell hypertrophy, and cardiovascular remodeling in controlled experimental settings. It is not suitable for diagnostic or therapeutic applications. Researchers should adhere to product-specific protocols to maximize reproducibility and avoid common pitfalls associated with peptide solubility and stability.

• ML133 HCl: Elevating Kir2.1 Potassium Channel Research Preci

  2026-04-28

  Explore how ML133 HCl, a selective potassium channel inhibitor, enables unprecedented mechanistic clarity in pulmonary artery smooth muscle cell research. This article offers a technical deep-dive and new assay recommendations, distinguishing itself from existing coverage.

• N-Glycosylation of MerTK Drives HCC Progression: Insights an

  2026-04-28

  This study demonstrates that N-glycosylation stabilizes MerTK, supporting hepatocellular carcinoma (HCC) cell survival and tumor growth. The findings establish MerTK glycosylation as a key oncogenic mechanism and suggest that N-glycosylation inhibition may offer a promising strategy for HCC intervention.

• Methyl-β-cyclodextrin: Practical Guide for Membrane Studies

  2026-04-27

  Methyl-β-cyclodextrin is a high-purity reagent used to selectively extract cholesterol and other lipids from cell membranes, enabling targeted studies of membrane fluidity, lipid raft organization, and cholesterol-dependent signaling. It is intended for precise experimental workflows in basic research, not for diagnostic or therapeutic applications.

• Leptin (116-130), amide, mouse: Bridging Mechanism and Strat

  2026-04-27

  This thought-leadership article provides translational researchers with a mechanistic and strategic framework for deploying Leptin (116-130), amide, mouse in metabolic and immunometabolic research. By weaving together peptide biology, experimental design, and competitive context, it offers actionable guidance beyond conventional product summaries, highlighting protocol optimization and future research pathways.

• Tea Polyphenol Nanoparticles Target AAA via Precision Drug D

  2026-04-26

  This study introduces bioactive tea polyphenol nanoparticles modified with cRGD for targeted doxycycline delivery to abdominal aortic aneurysm (AAA) lesions. The approach achieves synergistic anti-inflammatory, antioxidant, and anti-MMP effects, advancing the therapeutic potential for AAA beyond current systemic drug limitations.

• Translating PI3K Inhibition: Mechanistic Precision with GDC-

  2026-04-25

  This article provides translational researchers with evidence-driven strategies for leveraging GDC-0941, a selective class I PI3K inhibitor, to dissect and inhibit oncogenic PI3K/Akt signaling. We blend deep mechanistic insight, validated experimental protocols, and strategic guidance—contextualized by recent literature—to optimize research on therapy-resistant cancers. By integrating best practices, competitive analyses, and forward-looking clinical perspectives, this discussion advances beyond standard product descriptions and guides the next generation of translational oncology studies.

• ACE Inhibitor-Mediated Angioedema: Mechanisms and Clinical I

  2026-04-24

  This article reviews recent findings on angioedema associated with angiotensin-converting enzyme inhibitors (ACEi), focusing on the underlying bradykinin-mediated mechanisms, risk factors, and clinical management challenges. The study highlights the importance of genetic predispositions and evaluates current evidence on treatment strategies, guiding future research and clinical practice.

• Charge-Reversed Exosomes Enable Targeted mRNA Delivery to Ca

  2026-04-24

  Zhang et al. have developed surface-engineered, charge-reversed exosomes that facilitate efficient, non-viral delivery of enhanced green fluorescent protein (EGFP) mRNA into cartilage for osteoarthritis treatment. This approach overcomes the dense, negatively charged cartilage matrix, enabling deep tissue penetration and robust chondrocyte transfection—demonstrating a promising translational strategy for targeted gene therapy.

• D-Luciferin Sodium Salt: Transforming Bioluminescence Imagin

  2026-04-23

  D-Luciferin sodium salt empowers next-generation bioluminescent assays for real-time, non-invasive cellular analysis in oncology and metabolic research. Leveraging high solubility and robust ATP-dependent luminescence, it accelerates workflows from CAR-macrophage immunotherapy discovery to in vivo tumor monitoring.

• Angiotensin II in Hypertension and Vascular Remodeling Resea

  2026-04-23

  Angiotensin II (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe) is a gold-standard tool for dissecting hypertension and cardiovascular remodeling mechanisms. This article bridges cutting-edge protocol enhancements, troubleshooting, and translational insights, leveraging APExBIO’s validated Angiotensin II for reproducible, data-driven vascular research.

• Auranofin: Applied Protocols for TrxR Inhibition in Cancer R

  2026-04-22

  Auranofin, a gold-standard thioredoxin reductase inhibitor, empowers researchers to dissect redox biology and induce apoptosis with high reproducibility. This article delivers actionable protocols, troubleshooting insights, and a direct translation of breakthrough cytoskeleton-autophagy research for optimized experimental design.

15999 records 1/1067 page Next 12345 下5页 Last page